… Abstract: Background: Anti-tumor necrosis factor (anti-TNF) … Characteristics of the main
randomized controlled trials … 21 (5.3%) patients had infusion reactions leading to drug withdrawal …

… De-escalating therapy, the role of therapeutic drug monitoring and the use of biosimilars, …
By this local mode of action the systemic side effects of anti-TNF can be avoided [Citation103]. …

… Citation13 This review summarizes the clinical pharmacology… -controlled, induction RCT,
anti-TNF-naive patients with … the paper and agree to be accountable for all aspects of the …

… An insufficient understanding of the characteristics and use of biosimilars became evident in
a … The US Food & Drug Administration (FDA) defines a biosimilar as a biological product that …

… of biosimilars of the anti-TNF agents allow drug costs to be … used in all patients initiating an
anti-TNF agent as a means to … dosing based on clinical features (the maintenance phase). In …

… efficacy and side effects of a biosimilar are anticipated to be … between an anti-TNF biosimilar
and its RP. Although most … as hastened anti-TNF clearance in IBD is fecal loss of drug. Fecal …

… Other molecular aspects of pharmacology, which add an additional layer of complexity to …
to be resolved after discontinuation of the drug. Paradoxically, anti-TNF-α agents have been …

… expert’s review have expressed concerns to the concept of automatic extrapolation of
biosimilar anti-TNF-a … Clinical and scientific aspects related to biosimilars in inflammatory bowel …

… either IFX dosing based on their clinical features (n = 123) or a … This resulted in a 28 %
reduction in drug costs from prior to dose … Moreover, with the increasing use of IFX biosimilars, …

… Biosimilar anti-TNF monoclonal antibodies are increasingly used. Anti-TNF therapies are …
Psoriasis is a relatively common side effect of anti-TNF therapy, with 1.5%-5% of patients …